![The World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI). Click here to learn more.]({"type":"image" , "src" : "/sda/112382/JournalAd-COGI2024-Leaderboard.jpg"})
References
- Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine 10:942–949.
- Deniger DC, Maiti SN, Mi T, Switzer KC, Ramachandran V, Hurton LV, et al. 2014. Activating and propagating polyclonal Gamma Delta T cells with broad specificity for malignancies. Clinical Cancer Research 20:5708–5719.
- Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology 3:991–998.
- Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. 2007. Estimates of the cancer incidence and mortality in Europe in 2006. Annals of Oncology 18:581–592.
- Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. 2007. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America 104:3360–3365.
- Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. 2012. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecologic Oncology 124:192–198.
- Leffers N, Gooden MJM, de Jong RA, Hoogeboom B-N, ten Hoor KA, Hollema H, et al. 2009. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunology, Immunotherapy: CII 58:449–459.
- Negus R, Stamp GW, Hadley J, Balkwill FR. 1997. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of CC chemokines. The American Journal of Pathology 150:1723–1734.
- Qayyum S, Bullock GC, Swerdlow SH, Brower R, Nikiforova M, Aggarwal N. 2019. Diagnostic utility of isolated tube C positivity in T-cell receptor β testing using BIOMED-2 primers. American Journal of Clinical Pathology 151:386–394.
- Raspollini MR, Castiglione F, Rossi Degl’innocenti D, Amunni G, Villanucci A, Garbini F, et al. 2005. Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Annals of Oncology 16:590–596.
- Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. 2005. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America 102:18538–18543.
- SEER9. 1975. Incidence & U.S. mortality 1975–2014. Available from: http://seer.cancer.gov/statfacts/html/ovary.html
- Stumpf M, Hasenburg A, Riener M-O, Jütting U, Wang C, Shen Y, et al. 2009. Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. British Journal of Cancer 101:1513–1521.
- Tomsová M, Melichar B, Sedláková I, Steiner I. 2008. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecologic Oncology 108:415–420.
- Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. 2003. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New England Journal of Medicine 348:203–213.
- Zhang S, Ke X, Zeng S, Wu M, Lou J, Wu L, et al. 2015. Analysis of CD8+ Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment. Cellular & Molecular Immunology 12:580–591.